US prices of some pso­ri­a­sis drugs need to be low­ered to match ben­e­fits, new study says

The prices of drugs for pso­ri­a­sis need to be re­duced by about 71% to match their ef­fi­ca­cy, re­searchers from Har­vard Med­ical School and the Brigham and Women’s Hos­pi­tal said in a study pub­lished in JA­MA Der­ma­tol­ogy on Wednes­day.

The re­searchers looked at the net prices of 11 bi­o­log­ics and two biosim­i­lars for pso­ri­a­sis, which ranged from $1,664 to $79,277 per year, find­ing that ef­fi­ca­cy in the clin­ic didn’t match some of the high prices, ac­cord­ing to the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.